文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

单倍体供者年龄对移植结局的影响:单倍体相合移植与脐血移植的比较分析

Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.
PubMed 文献 · Blood Adv · 2025-01-01

基于日本登记数据,分析5161例16至70岁首次接受异基因造血干细胞移植的急性白血病、骨髓增生异常综合征或慢性髓性白血病患者,比较PTCY-haplo与CBT的移植后结局。在年龄≥50岁队列中,年轻供者(<40岁)的PTCY-haplo较CBT有更好的总生存、更低的非复发死亡率和更高的复发率;年老供者(≥40岁)的PTCY-haplo与CBT的OS、NRM和复发相当。在年龄<50岁队列中,PTCY-haplo与CBT的OS、NRM和复发相当。

要点

  • 在年龄≥50岁患者中,年轻供者PTCY-haplo较CBT的OS更优、NRM更低但复发率更高。
  • 在年龄≥50岁患者中,年老供者PTCY-haplo与CBT的OS、NRM和复发相当。
  • 在年龄<50岁患者中,年轻和年老供者PTCY-haplo的OS、NRM和复发均与CBT相当。

核心结论

  • 年轻供者PTCY-haplo用于年龄≥50岁患者较CBT提供更好的临床结局。
  • 年老供者PTCY-haplo与CBT在年龄≥50岁患者中OS、NRM和复发相当。
  • 在年龄<50岁患者中,PTCY-haplo与CBT的OS、NRM和复发相当。

研究设计与样本

  • 基于日本登记数据的比较分析,纳入5161例16至70岁首次接受HSCT的急性白血病、骨髓增生异常综合征或慢性髓性白血病患者。
  • 单倍体供者按年龄分为年轻(<40岁)和年老(≥40岁),患者按年龄分为年轻(<50岁)和年老(≥50岁)队列。
  • 比较PTCY-haplo与CBT的移植后结局。

主要发现

  • 在年老队列中,年轻供者PTCY-haplo较CBT的OS为55.5% vs 50.8%(P = .006),NRM为17.3% vs 28.6%(P < .001),复发率为33.0% vs 24.9%(P = .017)。
  • 在年老队列中,年老供者PTCY-haplo与CBT的OS为44.1% vs 50.8%(P = 1.00),NRM为27.3% vs 28.6%(P = 1.00),复发为29.2% vs 24.9%(P = .90)。
  • 在年轻队列中,年轻和年老供者PTCY-haplo的OS、NRM和复发均与CBT相当。
  • 在年老队列中,无论供者年龄,CBT的急性GVHD累积发生率高于PTCY-haplo。
  • 在年轻队列中,年轻供者PTCY-haplo的急性GVHD低于CBT。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched donors is the gold standard. However, haploidentical stem cell transplantation using posttransplant cyclophosphamide (PTCY-haplo) and cord blood transplants (CBTs) are alternatives when HLA-matched donors are not available. Using Japanese registry data, we evaluated the impact of haploidentical donor age on posttransplant outcomes by comparing PTCY-haplo and CBT. We analyzed data for 5161 patients aged 16 to 70 years who received their first HSCT for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia. Haploidentical donors were categorized as "younger" (aged <40 years) or "older" (aged ≥40 years), and the patients were divided into younger (aged <50 years) and older (aged ≥50 years) cohorts. In the older cohort, PTCY-haplo from younger donors had better overall survival (OS; 55.5% vs 50.8%, P = .006), lower nonrelapse mortality (NRM; 17.3% vs 28.6%, P < .001), and higher relapse rates (33.0% vs 24.9%, P = .017) than with CBT. PTCY-haplo from older donors had comparable OS (44.1% vs 50.8%, P = 1.00), NRM (27.3% vs 28.6%, P = 1.00), and relapse (29.2% vs 24.9%, P = .90) to that with CBT. In the younger cohort, PTCY-haplo from younger and older donors showed OS, NRM, and relapse comparable with CBT. In the older cohort, cumulative incidence of acute graft-versus-host disease (GVHD) was higher with CBT than with PTCY-haplo, regardless of donor age. However, in the younger cohort, acute GVHD was lower in PTCY-haplo from younger donors than with CBT. PTCY-haplo from younger donors to older patients offers better clinical outcomes than CBT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nagayama T, Fujiwara SI, Nishiwaki S, et al. Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation. Blood Adv. 2025. PMID: 40085961. doi:10.1182/bloodadvances.2024014938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。